Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, discusses the changing view of anti-HER2 therapies for patients with breast cancer.
Videos
William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses sequencing treatment in patients with metastatic castration resistant prostate cancer.
Debu Tripathy, MD, Co-Leader, Women's Cancer Program, Norris Comprehensive Cancer Center, University of Southern California, discusses two important trials in breast cancer looking at extended hormonal therapy.
Pamela Crilley, DO, explains the benefits and downfalls of prescribing tyrosine kinase inhibitors for the treatment of CML.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Real-World Data Link Higher Hemoglobin to Improved Survival in MDS
2
Early Relapse Guides Use of CAR T Vs Other Options in LBCL
3
Breast Cancer Test Using Proteomic Profiling and AI Demonstrates High Performance
4
Dr Mayer on Giredestrant's Success in Early Breast Cancer
5
